Multiple Sclerosis Clinical Trial

Genetic Evaluation of Natalizumab-Treated Patients With Progressive Multifocal Leukoencephalopathy

Summary

The purpose of this study is to explore host genetic mutations which may render individual subjects more susceptible (or resistant) to developing Progressive Multifocal Leukoencephalopathy (PML). Samples will also be collected to determine Deoxyribonucleic Acid (DNA) sequence of JC Virus (JCV). Analysis of the JC Virus (JCV) genome may provide information about viral genotypes that may be associated with higher pathogenicity, and help to identify individuals who may be at higher risk of developing Progressive Multifocal Leukoencephalopathy (PML) due to chronic infection with a more pathogenic variant of JC Virus (JCV).

View Full Description

Full Description

Deoxyribonucleic acid (DNA) will be analyzed from natalizumab-treated subjects who develop Progressive Multifocal Leukoencephalopathy (PML). The genetic analysis of the subjects will directly seek mutations that could identify subjects at risk.

View Eligibility Criteria

Eligibility Criteria

Key Inclusion Criteria:

Subjects who have confirmed PML while on treatment with Natalizumab

NOTE: Other protocol defined Inclusion/ Exclusion criteria may apply.

Study is for people with:

Multiple Sclerosis

Estimated Enrollment:

24

Study ID:

NCT01211639

Recruitment Status:

Terminated

Sponsor:

Biogen

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 10 Locations for this study

See Locations Near You

North Central Neurology Associates
Cullman Alabama, 35058, United States
Rocky Mountain MS Center at Anschutz Medical Campus University Colorado Denver
Aurora Colorado, 80045, United States
Rush Medical Center - Rush Multiple Sclerosis Center
Chicago Illinois, 60612, United States
St. Vincent Hospital, St. Vincent Neuroscience Institute
Indianapolis Indiana, 46260, United States
Central Neurology
Hastings Nebraska, 68901, United States
Clinical Research Center UH, The Nebraska Medical Center
Omaha Nebraska, 68105, United States
NYU Hospital for Joint Disease, MS Care Center
New York New York, 10003, United States
University of Rochester
Rochester New York, 14642, United States
Research Site
Cincinnati Ohio, 45208, United States
Neurology of Bend, LLC
Bend Oregon, 97701, United States
Research Site
Wuerzburg , , Germany

How clear is this clinincal trial information?

Study is for people with:

Multiple Sclerosis

Estimated Enrollment:

24

Study ID:

NCT01211639

Recruitment Status:

Terminated

Sponsor:


Biogen

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.

Please confirm you are a US based health care provider:

Yes, I am a health care Provider No, I am not a health care provider